Pfizer Prunes Its Pipeline And Creates A Stockpile Of Compounds For Deals
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer's latest pipeline refinement shows the drug maker is more than willing to stick with its professed "invest to win" core therapeutic areas after acquiring Wyeth, but the pharma giant is, nonetheless, hedging its bets by keeping some compounds from other areas for the sake of diversity
You may also be interested in...
"The Pink Sheet" – Most Notable Stories Of 2010
While industry mega-mergers occupied readers in 2009, the focus in 2010 shifted toward several evolving policy concerns and their impact on company strategy. Among these, more companies are looking at the opportunity for biosimilars created by the health care reform law's provision of a legal framework for product approval. But early analyses suggest that there is still a lot of work to do as FDA develops a guideline for industry on an abbreviated approval pathway.
"The Pink Sheet" – Most Notable Stories Of 2010
While industry mega-mergers occupied readers in 2009, the focus in 2010 shifted toward several evolving policy concerns and their impact on company strategy. Among these, more companies are looking at the opportunity for biosimilars created by the health care reform law's provision of a legal framework for product approval. But early analyses suggest that there is still a lot of work to do as FDA develops a guideline for industry on an abbreviated approval pathway.
In Another Pfizer Fire Sale, VC-Backed Conatus Acquires Idun's Idle Assets
Launched in 2006 by Idun's former management team, San Diego startup Conatus buys back a familiar property at a rock-bottom price.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: